Stocktoria
vTv Therapeutics Inc. VTVT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-07-30
vTv Therapeutics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $1.0M | $0 | $2.0M | $4.0M |
| R&D expense | $17.9M | $11.5M | $13.6M | $12.4M | $13.3M |
| Operating income | -$32.8M | -$24.2M | -$25.5M | -$22.5M | -$21.7M |
| Interest expense | — | — | $13,000 | $15,000 | $12,000 |
| Income tax | $0 | $100,000 | $0 | $200,000 | $115,000 |
| Net income | -$27.0M | -$18.5M | -$20.2M | -$19.2M | -$13.0M |
| Operating cash flow | -$25.3M | -$25.3M | -$19.1M | -$16.0M | -$19.3M |
| Free cash flow | — | -$25.3M | -$19.1M | -$16.0M | -$19.3M |
| Cash & equivalents | $88.9M | $36.7M | $9.4M | $12.1M | $13.4M |
| Total assets | $89.9M | $38.3M | $11.0M | $33.2M | $25.5M |
| Total liabilities | $25.5M | $24.0M | $29.6M | $27.4M | $10.3M |
| Shareholders' equity | $64.4M | $14.3M | -$24.7M | -$10.7M | -$9.7M |
Source: SEC EDGAR filings · CIK 0001641489 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.